medigraphic.com

2022, Número 3

<< Anterior Siguiente >>

Rev Hematol Mex 2022; 23 (3)


Mecanismos moleculares implicados en la patogénesis de la leucemia promielocítica aguda

Mondragón-Morales J, Santos-López FN

Idioma: Ingles.
Referencias bibliográficas: 30
Paginas: 159-168
Archivo PDF: 311.32 Kb.


RESUMEN

La leucemia promielocítica aguda es una neoplasia maligna hematológica caracterizada por una proliferación anormal de promielocitos en la médula ósea. Una mutación que involucra a los cromosomas 15 y 17 conduce a un gen de fusión PML/RARα anormal que causa gran parte de las características de la enfermedad. Los síntomas pueden ser inespecíficos, pero uno de los signos más comunes de la leucemia promielocítica aguda es el sangrado. Las citocinas liberadas por los promielocitos hacen que las plaquetas se activen y la quimioterapia puede potenciar esta respuesta inflamatoria, creando un ambiente proinflamatorio.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ryan MM. Acute promyelocytic leukemia: a summary. JAdv Pract Oncol 2018; 9 (2): 178-87.

  2. Bain BJ, Béné MC. Morphological and immunophenotypicclues to the WHO categories of acute myeloidleukaemia. Acta Haematol 2019; 141 (4): 232-44. doi:10.1159/000496097.

  3. Pollyea DA, Altman JK, Bhatt BR, Dixby D, Fathi AT. Acutemyeloid leukemia. Cancer Cytogenet 2010; 45-139.

  4. Yilmaz M, Kantarjian H, Ravandi F. Acute promyelocytic leukemiacurrent treatment algorithms. Blood Cancer J 2021;11 (6). https://doi.org/10.1038/s41408-021-00514-3.

  5. Noguera NI, Catalano G, Banella C, Divona M, Faraoni I,Ottone T, et al. Acute promyelocytic leukemia: Update onthe mechanisms of leukemogenesis , resistance and oninnovative treatment strategies. Cancers (Basel). 2019; 11(1591): 1-21. doi: 10.3390/cancers11101591.

  6. Testa U, Lo-Coco F. Prognostic factors in acute promyelocyticleukemia: strategies to define high-risk patients.Ann Hematol 2016; 95 (5): 673-80. doi: 10.1007/s00277-016-2622-1.

  7. Li S, Chen L, Jin W, Ma X, Ma Y, Dong F, et al. Influenceof body mass index on incidence and prognosis of acutemyeloid leukemia and acute promyelocytic leukemia: Ameta-analysis. Sci Rep 2017; 7 (1): 1-10. doi: 10.1038/s41598-017-18278-x.

  8. Gurnari C, Voso MT, Girardi K, Mastronuzzi A, StrocchioL. Acute promyelocytic leukemia in children: A model ofprecision medicine and chemotherapy-free therapy. Int JMol Sci 2021; 22 (2): 1-13. doi: 10.3390/ijms22020642.

  9. Papageorgiou C, Jourdi G, Adjambri E, Walborn A, PatelP, Fareed J, et al. Disseminated intravascular coagulation:An update on pathogenesis, diagnosis, and therapeuticstrategies. Clin Appl Thromb Hemost 2018; 24: 8S-28S.doi: 10.1177/1076029618806424.

  10. Ikezoe T. Pathogenesis of disseminated intravascular coagulationin patients with acute promyelocytic leukemia, andits treatment using recombinant human soluble thrombomodulin.Int J Hematol 2014; 100 (1): 27-37.

  11. Ten Cate H, Leader A. Management of disseminated intravascularcoagulation in acute leukemias. Hamostaseologie2021; 41 (2): 120-6. doi: 10.1055/a-1393-8302.

  12. Mardani R, Jafari Najaf Abadi MH, Motieian M, Taghizadeh-Boroujeni S, Bayat A, Farsinezhad A, et al. MicroRNA inleukemia: Tumor suppressors and oncogenes with prognosticpotential. J Cell Physiol 2019; 234 (6): 8465-86. doi:10.1002/jcp.27776.

  13. Zhang B, Pei Z, Wang H, Bai J, Wang J, Zhao Y, et al.Clinical value of serum miRNA in patients with acutepromyelocytic leukemia. J Oncol 2022; 2022. doi:10.1155/2022/7315879.

  14. Li S, Ma Y, Tan Y, Ma X, Zhao M, Chen B, et al. Profiling andfunctional analysis of circular RNAs in acute promyelocyticleukemia and their dynamic regulation during all-transretinoic acid treatment article. Cell Death Dis 2018; 9 (6).http://dx.doi.org/10.1038/s41419-018-0699-2

  15. Zamrodah Y. Harrisons Principles of Internal Medicine.2016; 15 (2): 1-23.

  16. Levi M. Pathogenesis and diagnosis of disseminated intravascularcoagulation. Vol. 40, Int J Lab Hematol 2018;15-20. doi: 10.1111/ijlh.12830.

  17. Parajuli S, Tuladhar A. Correlation of bone marrow aspirationand biopsy findings in diagnosing hematologicaldisorders - a study of 89 cases. J Pathol Nepal 2014; 4 (7):534-8. https://doi.org/10.3126/jpn.v4i7.10294.

  18. Chandra S, Chandra H. Comparison of bone marrow aspiratecytology, touch imprint cytology and trephine biopsyfor bone marrow evaluation. Hematol Rep 2011; 3 (3): 4-7.doi: 10.4081/hr.2011.e22.

  19. Gilotra M, Gupta M, Singh S, Sen R. Comparison of bonemarrow aspiration cytology with bone marrow trephinebiopsy histopathology: An observational study. J Lab Physicians

  20. 2017; 9 (03): 182-9. doi: 10.4103/JLP.JLP_117_16.20. Aanei CM, Veyrat-Masson R, Selicean C, Marian M, RigolletL, Trifa AP, et al. Database-guided analysis for immunophenotypicdiagnosis and follow-up of acute myeloid leukemiawith recurrent genetic abnormalities. Front Oncol 2021; 11:1-14. https://doi.org/10.3389/fonc.2021.746951.

  21. Shahmarvand N, Oak JS, Cascio MJ, Alcasid M, Goodman E,Medeiros BC, et al. A study of disseminated intravascularcoagulation in acute leukemia reveals markedly elevatedD-dimer levels are a sensitive indicator of acute promyelocyticleukemia. Int J Lab Hematol 2017; 39 (4): 375-83.doi: 10.1111/ijlh.12636.

  22. Morales MM, Agramonte Llanes OM, Rodríguez YT. Diagnosticusefulness of quantitative D-dimer. Rev CubanaHematol Inmunol Hemoter 2020; 36 (4): 1-17.

  23. Liang C, Qiao G, Liu Y, Tian L, Hui N, Li J, et al. Overviewof all-trans-retinoic acid (ATRA) and its analogues: Structures,activities, and mechanisms in acute promyelocyticleukaemia. Eur J Med Chem 2021; 220: 113451. https://doi.org/10.1016/j.ejmech.2021.113451.

  24. Kayser S, Schlenk RF, Platzbecker U. Management of patientswith acute promyelocytic leukemia. Leukemia 2018;32 (6): 1277-94. doi: 10.1038/s41375-018-0139-4.

  25. Kozono S, Lin YM, Seo HS, Pinch B, Lian X, Qiu C, et al. Arsenictargets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun2018; 9 (1). https://doi.org/10.1038/s41467-018-05402-2.

  26. Joubert N, Beck A, Dumontet C, Denevault-Sabourin C.Antibody – drug conjugates: The last decade 2020; 1-31.

  27. Goldenson BH, Goodman AM, Ball ED. Gemtuzumabozogamicin for the treatment of acute myeloid leukemiain adults. Expert Opin Biol Ther 2021; 21 (7): 849-62. doi:10.1080/14712598.2021.1825678.

  28. Sanz MA, Montesinos P. Advances in the management ofcoagulopathy in acute promyelocytic leukemia. ThrombRes 2020; 191 (September 2019): S63-7. https://doi.org/10.1016/S0049-3848(20)30399-6.

  29. Gasparovic L, Weiler S, Higi L, Burden AM. Incidence ofdifferentiation syndrome associated with treatment regimensin acute myeloid leukemia: A systematic review ofthe literature. J Clin Med 2020; 9 (10): 3342. doi: 10.3390/jcm9103342.

  30. Stahl M, Tallman MS. Differentiation syndrome in acutepromyelocytic leukaemia. Br J Haematol 2019; 187 (2):157-62. doi: 10.1111/bjh.16151.




2020     |     www.medigraphic.com